Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (monocyte progenitors) | 0.10 |
| chemistry Open Targets | compounds already reach it: sivelestat, depelestat, alvelestat +1 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 489 | 0.85 |
| pathways Reactome | 8 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 10071
Sealed predictions
- ELANE in dopamine neurons, braak+0.08 (p 0.838) → +0.14 (p 0.722)receipt 10079
Swarm cases
receipt 10079: ELANE in dopamine neurons, braak
- power
- full sample +0.10 (p 0.690, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.09 (p 0.722, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.677, n 18). could be the mix.
- skeptic
- leave-one-out range -0.03 to +0.26, sign flips 3; without severely affected donors +0.10 (p 0.690, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ELANE in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts